Boston Scientific Slips 6% on Cyberattack: Time to Buy or Wait?

Boston Scientific (BSX) saw its stock drop 5.81% to close at $42.44 on October 28, following the company's announcement that a cyberattack significantly impacted its third-quarter results and forced it to lower fourth-quarter and full-year guidance. Trading volume surged to 66.8 million shares, about 234% above the three-month average, indicating heightened investor concern.

The cyberattack caused an eight-day disruption that management estimates cost the company 300 basis points in sales growth and $0.07 in adjusted earnings per share (EPS). For Q3, Boston Scientific reported sales growth of just 1.5% and adjusted EPS of $0.73, both falling short of its guided range of 3% to 5% sales growth and $0.80 to $0.82 EPS.

Looking ahead, the company does not expect an immediate rebound. It guided for 3.75% sales growth in 2026 and indicated that a slow rebuilding process is more likely over the next year or two. CEO Mahoney stated, "We believe that 2027 will be the trough in the cycle and we have several investments and new innovations coming over the course of the next 3 years."

Despite the near-term challenges, Boston Scientific's shares now trade at just 13 times forward earnings, a relatively low valuation that could attract value investors. Additionally, the company has a pending acquisition of Penumbra, which, if integrated successfully, could provide upside.

The broader market showed modest gains, with the S&P 500 up 0.28% and the Nasdaq Composite up 0.27%. In the medical devices sector, Medtronic (MDT) rose 0.93% to $94.82, while Abbott Laboratories (ABT) dipped 0.42% to $102.67 amid sector-wide outlook pressure.

The cyberattack's impact on Boston Scientific goes beyond a one-time disruption. The company's lowered guidance and cautious outlook suggest that the recovery may take longer than initially hoped, with management pointing to 2027 as the trough year. This implies that earnings growth could remain subdued for the next couple of years, which may weigh on the stock price in the near term.

However, the sharp sell-off has brought Boston Scientific's valuation down to 13 times forward earnings, which is relatively cheap for a medical device company with a history of innovation and growth. This low bar could mean that any positive surprise—such as faster-than-expected recovery or successful integration of the Penumbra acquisition—could lead to a significant rebound in the stock.

Investors should also consider the competitive landscape. Medtronic and Abbott Laboratories, peers in the medical devices sector, may not be directly affected by Boston Scientific's cyberattack, but the incident highlights the growing risk of cybersecurity threats for all companies. Medtronic's stock rose slightly, while Abbott dipped, reflecting mixed sentiment.

In the long run, Boston Scientific's investments in new innovations and its pending acquisition could strengthen its position, but execution risks remain. The cyberattack serves as a reminder of operational vulnerabilities that could impact future performance.

For now, the stock's movement will likely depend on the company's ability to demonstrate progress in recovering from the cyberattack and delivering on its guidance. Until then, investors may adopt a wait-and-see approach.